Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Women with PCOS often have insulin resistance, abnormal lipid levels, and a higher risk of diabetes and heart disease; lifestyle changes and medication like metformin can help manage these risks.

This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.

This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.

This consensus report reviews current knowledge and identifies knowledge gaps concerning the various health aspects of polycystic ovary syndrome, without presenting new clinical findings.

Managing metabolic syndrome needs both lifestyle changes and medical treatments.

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

This paper reviews the diagnostic criteria, associated morbidities, and possible evolutionary advantages of polycystic ovary syndrome, but does not report any new findings.

This review emphasizes the need for comprehensive guidelines to address the cardiometabolic and psychological features of polycystic ovary syndrome, alongside its reproductive aspects, and reports no new results.

This review discusses the current understanding of polycystic ovary syndrome, focusing on its epidemiology, pathophysiology, diagnosis, management, and future research directions, but reports no new clinical results.

This review examines the relationship between polycystic ovary syndrome and cardiovascular disease risk, but reports no new clinical findings; the panel calls for guidelines to prevent CVD in this population.

This paper reviews the diagnostic criteria, etiological factors, and treatment approaches for PCOS, highlighting the importance of considering metabolic issues such as insulin resistance and obesity, but reports no new findings.

This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.

This review discusses the potential impact of endocrine-disrupting chemicals and body size on pubertal onset and progression, highlighting critical gaps and priorities for future research without presenting new clinical results.

This abstract reviews the characteristics and health risks associated with polycystic ovary syndrome and does not report new findings, highlighting the syndrome's multifactorial nature.

This review discusses the complex etiology of polycystic ovary syndrome (PCOS), highlighting its association with insulin resistance and hyperandrogenism, but reports no clinical findings; the authors suggest further investigation of the pathophysiological mechanisms.

This review discusses the multifaceted actions of metformin in polycystic ovary syndrome and reports no new clinical results; the authors emphasize metformin's potential benefits in both cardiometabolic and reproductive aspects of PCOS.

This study found that lifestyle interventions improved body composition, hyperandrogenism, and insulin resistance in women with PCOS, but did not affect glucose tolerance, lipid profiles, or clinical reproductive outcomes.

This review discusses how women with PCOS have an increased risk of insulin resistance and cardiometabolic features regardless of body fat, and calls for targeted prevention and management strategies.

This study found that women with polycystic ovary syndrome have higher rates of nonalcoholic fatty liver disease, with androgen excess contributing to the risk.

This study found that young indigenous South Asian women with polycystic ovary syndrome are more likely to be centrally obese and have metabolic syndrome, particularly with increasing age, higher BMI, and acanthosis nigricans.

This study found that parents of women with PCOS have a higher prevalence of insulin resistance and Type II diabetes than parents of healthy women.

This article reviews the diagnostic criteria and prevalence of PCOS, emphasizing its status as the most common endocrine disorder among women of reproductive age, with no new clinical results reported.

This meta-analysis found that lower serum SHBG levels are associated with an increased risk of PCOS, and improving SHBG levels through treatment may reduce PCOS complications.

This review discusses the essential roles and complex regulation of PP2A in various physiological processes and reports no clinical results; the authors highlight the need for further mouse model research to explore PP2A's therapeutic potential.

This review discusses the multifactorial origins and pathophysiology of PCOS and highlights the effectiveness of lifestyle modifications as a first-line intervention, reporting no new research results.

This review discusses medical treatments for hirsutism, focusing on oral contraceptives and other therapies, but reports no new results; the authors emphasize the lack of evidence for insulin sensitizers in treating hirsutism alone.

In this study, short-term liraglutide treatment led to significant weight loss in obese women with newly diagnosed PCOS and a higher metabolic risk profile compared to metformin.

This article discusses the association between hypertension and polycystic ovary syndrome, highlighting the need for managing related risk factors, but reports no new clinical results.

This review discusses the relationship between SHBG, NAFLD, and PCOS and reports no new clinical results; the authors highlight low hepatic SHBG production as potentially significant in PCOS pathogenesis.

This study found that a 6-month treatment with either metformin or rosiglitazone significantly improved endothelial function in young women with PCOS without any one drug being superior.